Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
cell therapy β’ autoimmune β’ lupus
51 - 200 employees
Founded 2019
𧬠Biotechnology
π Pharmaceuticals
π¬ Science
π° $85M Series B on 2022-01
November 23
Oversee medical writing activities at Kyverna Therapeutics, focusing on autoimmune therapies. Requires leadership and strategic thinking in regulatory submissions and publications.
πΊπΈ United States β Remote
π° $85M Series B on 2022-01
β° Full Time
π΄ Lead
βοΈ Content Writer
November 8
Develop engineered T cell-based therapies for autoimmune diseases.
πΊπΈ United States β Remote
π΅ $260k - $350k / year
π° $85M Series B on 2022-01
β° Full Time
π Senior
π¨ββοΈ Medical Director